# Antipsychotics for NEET PG Psychiatry: FGA vs SGA, Clozapine and Agranulocytosis, EPS, Tardive Dyskinesia, NMS, Metabolic Monitoring

Source: https://tracknation.in/story/antipsychotics-for-neet-pg-psychiatry-fga-vs-sga-clozapine-and-agranulocytosis-eps-tardive-dyskinesia-nms-metabolic-monitoring (TrackNation — free UPSC notes with PYQs)

> NEET PG Psychiatry: first- and second-generation antipsychotics, potency, clozapine with its blood monitoring, acute dystonia, parkinsonism, akathisia, tardive dyskinesia, neuroleptic malignant syndrome, prolactin, QT and metabolic effects, with a diagram, hooks, vignette MCQs and cards.

## Start Here

🎯 **Exam priority: High.** *Expect: high- vs low-potency drugs, which side effect fits which vignette (oculogyric crisis, restlessness,
lip-smacking, rigidity with fever), the drug for each, clozapine indications and agranulocytosis monitoring, risperidone and prolactin, SGAs and
metabolic syndrome, QT and dementia warnings.*

CBME mapping: **PS 4.1, PS 13**. Receptor pharmacology is also in Pharmacology.

*Antipsychotic adverse effects and treatment; FGA vs SGA; clozapine; SGA metabolic monitoring. Drawn by TrackNation.*

## Classes and Choice

- **First-generation (FGA)**: high-potency drugs such as **haloperidol** bind dopamine receptors strongly (more extrapyramidal
effects); low-potency drugs such as **chlorpromazine** act more on alpha-adrenergic, muscarinic and histamine receptors. FGAs cause sedation,
cognitive blunting, EPS, raised prolactin (galactorrhoea), weight gain and a lower seizure threshold, but remain useful in acute psychosis and when cost
matters.

- **Second-generation (SGA)**: fewer EPS and much less tardive dyskinesia, little prolactin rise (except **risperidone**, which
raises prolactin as much as FGAs) but more **metabolic syndrome** — weight gain, dyslipidaemia, type 2 diabetes. Olanzapine is sedating.
Long-acting injections: aripiprazole, olanzapine, paliperidone, risperidone.

- About 30% do not respond to FGAs. **Clozapine** works in about 40% of resistant patients, reduces suicidality and negative symptoms
and hardly causes EPS or TD — but risks **agranulocytosis (< 1%)** needing WBC checks weekly for 6 months, then 2-weekly, then monthly after a
year, plus myocarditis, dose-related seizures, sedation, hypotension, constipation, weight gain and excess salivation.

- QT prolongation: thioridazine, haloperidol, olanzapine, risperidone, ziprasidone. All antipsychotics increase mortality in older adults with
dementia. Xanomeline (with trospium) is the first antipsychotic with no D2 action.

## Adverse Effects and Their Treatment

- **Acute dystonia** — oculogyric crisis, torticollis: IV/IM benztropine or diphenhydramine. **Laryngeal dystonia**: IV
lorazepam, intubation if needed.

- **Parkinsonism / akinesia**: oral benztropine; consider a lower-potency drug. **Akathisia** (motor restlessness — a common reason
for stopping treatment): **propranolol**, dose reduction or switching.

- **Tardive dyskinesia**: lip and tongue puckering, finger movements, limb writhing; with FGAs the risk rises about **5% per year**
of exposure and it may persist after stopping. Track with the AIMS scale; switch to clozapine or quetiapine; **valbenazine** (VMAT2
inhibitor) is approved.

- **Neuroleptic malignant syndrome**: rigidity, hyperthermia, autonomic instability, high creatine kinase; possible with all
antipsychotics (more with FGAs). Stop the drug, cool rapidly, support; bromocriptine, amantadine, dantrolene.

- **Metabolic monitoring for SGAs**: before starting, record weight, waist, BP, fasting glucose and lipids and family history of diabetes;
then monitor weight, BMI and glucose. At high metabolic risk prefer aripiprazole, lurasidone, ziprasidone, cariprazine or lumateperone. ICMR also asks
about weight gain, menstrual and sexual dysfunction at each review.

## Traps the Examiner Sets

- Restlessness after starting haloperidol = akathisia → propranolol, not more antipsychotic.

- Rigidity + fever + high CK = NMS → stop the drug.

- Clozapine: blood counts; risperidone: prolactin; olanzapine: weight and sedation.

- Tardive dyskinesia may not go away after stopping the drug.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **'Dystonia → Diphenhydramine or benztropine; Akathisia → A beta-blocker'** — EPS treatment

- 🧠 **NMS = 'Rigid, Hot, Unstable, CK sky-high'** — NMS

- 🧠 **Akathisia: 'restless legs? Propranolol'** — akathisia

- 🧠 **Clozapine 'CLOZ': Count the WBC, Lower suicide, Overcomes resistance, Zero EPS (almost)** — clozapine

- 🧠 **'Risperidone Raises prolactin; Olanzapine Overeats'** — SGA side effects

## Rapid-Revision Cards

- Haloperidol: D2, more EPS.

- Chlorpromazine: sedation, anticholinergic, α-block.

- Less EPS, more metabolic.

- Prolactin like FGAs.

- Sedation, weight.

- ~30% to FGAs.

- ~40% of resistant; ↓ suicide.

- Agranulocytosis < 1%.

- Weekly 6 mo → 2-weekly → monthly after 1 y.

- Myocarditis, seizures, salivation.

- Benztropine/diphenhydramine IV/IM.

- IV lorazepam; airway.

- Propranolol.

- Benztropine; lower potency.

- ~5%/year on FGAs; may persist.

- Valbenazine.

- Rigidity, fever, autonomic, CK↑.

- Stop drug, cool, bromocriptine, dantrolene.

- Weight, waist, BP, glucose, lipids.

- Thioridazine, haloperidol, ziprasidone.

- Antipsychotics ↑ mortality.

## Sources

*Facts in this article were checked against these documents.*

- MSD Manual Professional: Antipsychotic Medications — Merck & Co. (MSD Manuals), reviewed 2025–26 (link)

- Standard Treatment Workflow: Psychosis — Indian Council of Medical Research, DHR, 2019 (link)

- Competency Based Undergraduate Curriculum, Psychiatry (PS 4, PS 13) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** High-potency first-generation antipsychotics such as haloperidol differ from low-potency ones in having

- (a) higher dopamine affinity and less alpha-adrenergic/muscarinic action

- (b) no extrapyramidal effects

- (c) more anticholinergic effects

- (d) more sedation

**Answer: (a)** — So more EPS.

**Q2.** A low-potency first-generation antipsychotic is

- (a) aripiprazole

- (b) haloperidol

- (c) risperidone

- (d) chlorpromazine

**Answer: (d)** — More adrenergic, muscarinic, histamine effects.

**Q3.** Compared with FGAs, second-generation antipsychotics

- (a) raise prolactin more in all cases

- (b) never affect weight

- (c) cause more tardive dyskinesia

- (d) cause fewer EPS but more metabolic syndrome

**Answer: (d)** — Weight, lipids, diabetes.

**Q4.** A woman on an antipsychotic develops galactorrhoea and missed periods. The SGA most likely to do this, as much as FGAs, is

- (a) clozapine

- (b) quetiapine

- (c) aripiprazole

- (d) risperidone

**Answer: (d)** — Prolactin elevation.

**Q5.** About what proportion of patients with schizophrenia do not respond to FGAs?

- (a) about 70%

- (b) about 1%

- (c) about 30%

- (d) none

**Answer: (c)** — Consider clozapine.

**Q6.** The antipsychotic effective in about 40% of treatment-resistant patients is

- (a) haloperidol

- (b) risperidone

- (c) clozapine

- (d) chlorpromazine

**Answer: (c)** — Only drug proven after FGA/SGA failure.

**Q7.** Weekly blood counts are required for the first 6 months of clozapine because of

- (a) agranulocytosis

- (b) thrombocytosis

- (c) hepatitis

- (d) hyperkalaemia

**Answer: (a)** — < 1% of patients.

**Q8.** Besides agranulocytosis, a serious cardiac adverse effect of clozapine is

- (a) myocarditis

- (b) pericardial tamponade

- (c) heart block

- (d) aortic stenosis

**Answer: (a)** — Also seizures, salivation.

**Q9.** Clozapine can cause seizures that are

- (a) only in children

- (b) caused by withdrawal only

- (c) dose-dependent

- (d) never seen

**Answer: (c)** — Higher doses, higher risk.

**Q10.** Clozapine has a special role in patients with schizophrenia who

- (a) have diabetes

- (b) are at high suicide risk

- (c) need sedation for sleep

- (d) have mild first episodes

**Answer: (b)** — It reduces suicidality.

**Q11.** A young man given haloperidol develops sustained upward eye deviation and neck twisting. Treatment is

- (a) dantrolene

- (b) propranolol

- (c) IV/IM benztropine or diphenhydramine

- (d) stop all drugs and wait

**Answer: (c)** — Acute dystonia.

**Q12.** Acute dystonia affecting the larynx with stridor is treated with

- (a) IV lorazepam, intubating if needed

- (b) valbenazine

- (c) oral benztropine next day

- (d) propranolol

**Answer: (a)** — Airway emergency.

**Q13.** A patient on an antipsychotic feels an inner urge to keep moving and cannot sit still. The drug of choice is

- (a) more haloperidol

- (b) dantrolene

- (c) valbenazine

- (d) propranolol

**Answer: (d)** — Akathisia; can cause non-adherence.

**Q14.** After years of FGA treatment, a patient shows lip puckering, tongue movements and writhing fingers. The diagnosis is

- (a) NMS

- (b) akathisia

- (c) acute dystonia

- (d) tardive dyskinesia

**Answer: (d)** — Can persist after stopping.

**Q15.** With FGAs, the risk of tardive dyskinesia increases by about

- (a) it does not change

- (b) 50% per month

- (c) 1% total

- (d) 5% per year of exposure

**Answer: (d)** — Cumulative risk.

**Q16.** A scale used to track tardive dyskinesia is the

- (a) Abnormal Involuntary Movement Scale (AIMS)

- (b) Y-BOCS

- (c) MMSE

- (d) HAM-D

**Answer: (a)** — Includes tongue protrusion.

**Q17.** A drug approved specifically for tardive dyskinesia is

- (a) benztropine

- (b) lithium

- (c) valbenazine (VMAT2 inhibitor)

- (d) haloperidol

**Answer: (c)** — Also deutetrabenazine.

**Q18.** A patient with tardive dyskinesia who still needs an antipsychotic can be switched to

- (a) clozapine or quetiapine

- (b) haloperidol

- (c) chlorpromazine

- (d) fluphenazine

**Answer: (a)** — Lower motor risk.

**Q19.** A patient on haloperidol develops high fever, marked muscle rigidity, fluctuating blood pressure and a very high CK. The diagnosis is

- (a) malignant hyperthermia of anaesthesia

- (b) neuroleptic malignant syndrome

- (c) acute dystonia

- (d) serotonin syndrome

**Answer: (b)** — Possible with all antipsychotics.

**Q20.** Management of NMS includes

- (a) starting lithium

- (b) increasing the antipsychotic

- (c) adding benztropine only

- (d) stopping the antipsychotic, rapid cooling, and bromocriptine or dantrolene

**Answer: (d)** — Supportive care.

**Q21.** NMS is more common with

- (a) lithium only

- (b) SSRIs

- (c) first-generation antipsychotics

- (d) benzodiazepines

**Answer: (c)** — But any antipsychotic can cause it.

**Q22.** Before starting a second-generation antipsychotic, baseline checks should include

- (a) nothing

- (b) weight, waist, BP, fasting glucose and lipids

- (c) ECG only

- (d) thyroid only

**Answer: (b)** — Then periodic monitoring.

**Q23.** For a patient with obesity and pre-diabetes, an antipsychotic with lower metabolic risk is

- (a) aripiprazole

- (b) clozapine

- (c) chlorpromazine

- (d) olanzapine

**Answer: (a)** — Also lurasidone, ziprasidone.

**Q24.** An agitated patient with insomnia might be given an SGA with relatively high sedation, such as

- (a) aripiprazole

- (b) olanzapine

- (c) ziprasidone

- (d) lurasidone

**Answer: (b)** — Choose by side-effect profile.

**Q25.** Which antipsychotics are available as long-acting injections?

- (a) quetiapine only

- (b) clozapine only

- (c) aripiprazole, olanzapine, paliperidone, risperidone

- (d) none

**Answer: (c)** — Helps adherence.

**Q26.** Antipsychotics that can prolong the QT interval include

- (a) none

- (b) aripiprazole only

- (c) lithium

- (d) thioridazine, haloperidol and ziprasidone

**Answer: (d)** — Risk of fatal arrhythmia.

**Q27.** In older adults with dementia, antipsychotics are associated with

- (a) better memory

- (b) improved survival

- (c) increased mortality

- (d) no change

**Answer: (c)** — Both FGAs and SGAs.

**Q28.** First-generation antipsychotics still have a role mainly in

- (a) dementia

- (b) pregnancy only

- (c) tardive dyskinesia

- (d) acute psychosis and when cost matters

**Answer: (d)** — SGAs widely used otherwise.

**Q29.** The first antipsychotic with no action at dopamine D2 receptors is

- (a) xanomeline (with trospium)

- (b) aripiprazole

- (c) haloperidol

- (d) clozapine

**Answer: (a)** — Muscarinic agonist.

**Q30.** Tardive dyskinesia, once established, may

- (a) always resolve in a week

- (b) respond to more antipsychotic

- (c) persist indefinitely even after stopping the drug

- (d) be prevented by benztropine

**Answer: (c)** — Hence prevention and monitoring.

### Active Recall

From memory: compare first- and second-generation antipsychotics, describe clozapine's uses and risks, and name each extrapyramidal adverse effect, tardive dyskinesia and NMS with their treatment, plus metabolic monitoring.
